AC Immune to Present Advances in Alzheimer’s Programs Targeting Abeta and Tau at the 15th CTAD Conference


AC Immune to Present Advances in Alzheimer’s Programs Targeting Abeta and Tau at the 15th CTAD Conference

  • New generation SupraAntigen® a liposomal vaccine platform increases immunization against disease targets in Alzheimer’s disease
  • New Phospho-Tau Vaccine Data Confirm Safety, Tolerability and Immunogenicity of ACI-35 and JACI-35, Developed in Collaboration with Janssen Pharmaceuticals
  • Genentech/Roche Collaborative Partner to Present Pharmacodynamic Effects of Semorinemab on Plasma and CSF Tau Biomarkers from the “Lauriet” Phase 2 Trial in Mild-to-Moderate Alzheimer’s Disease
  • Banner Alzheimer’s Institute to share plasma biomarker data from API-ADAD trial evaluating anti-Abeta antibody crenezumab

Lausanne, Switzerland, November 23, 2022 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations of its SupraAntigen vaccine technology®and its anti-Tau and anti-Abeta experimental candidates, at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco, California (USA) and online, from November 29 to December 2, 2022.

During the conference, Professor Johannes Streffer, Medical Director of AC Immune, will present interim data from the anti-phospho-Tau vaccine program currently in a phase 1b/2a study. Dr. Marie Kosco-Vilbois, Chief Scientific Officer, will detail the company’s proprietary SupraAntigen® technology platform, enabling liposome-based generation of conformation-specific antibodies and active immunotherapies.

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented“These CTAD presentations showcase the ability of our experienced team to discover and develop new active targeted vaccines using our SupraAntigen®-Technological platform V. SupraAntigen® Clinical trials have shown that the vaccines are safe and generate broad polyclonal antibody responses that are highly specific for different species of neurotoxic proteins in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. This is exemplified by the polyclonal response induced by ACI-24.060, with antibodies that preferentially bind to clinically validated toxic Abeta species, oligomers and Abeta pyroglutamate, established hallmarks of AD progression. We look forward to presenting new data from our SupraAntigen at CTAD® pTau vaccine ACI-35.030, highlighting its safety, tolerability and immunogenicity profile.

Additionally, there will be fluid biomarker presentations covering the partnered programs for crenezumab anti-Abeta phase 2 antibody and semorinemab phase 2 anti-Tau antibody, both in partnership with member Genentech. from the Roche group; as well as data from the PI-2620 diagnostic candidate of the Tau Positron Emission Tomography (PET) tracer, in partnership with Life Molecular Imaging (LMI).

AC Immune pipeline at CTAD 2022

Abstract Title

  • Type of presentation
  • Presentation date, time (PT)
  • Author/presenter

ACI-35.030 Tau vaccine

ACI-35.030 and JACI-35.064, two new anti-phospho-Tau vaccines for the treatment of Alzheimer’s disease: interim phase 1b/2a data on safety, tolerability and immunogenicity

  • Oral communication
  • OC1
  • Wed, November 30, 11:00 a.m. – 11:15 a.m.
  • Johannes Streffer, AC Immune

SupraAntigen® Technology platform

Benefits of the new generation of SupraAntigen® liposomal vaccine platform to immunize against pathological targets of Alzheimer’s disease

  • Oral communication
  • OC39
  • Fri, Dec 2, 4:05 p.m. – 4:20 p.m.
  • Marie Kosco-Vilbois, AC Immune

Crenezumab anti-Abeta antibody

Plasma Biomarker Results from the Alzheimer’s Prevention Initiative Colombian Autosomal Dominant Alzheimer’s Disease Trial

  • Oral communication
  • OC23
  • Thu 01 December, 3:45 p.m. – 4:00 p.m.
  • Eric M. Reiman, Banner Alzheimer Institute

Anti-Tau semorinemab antibody

Pharmacodynamic effects of semorinemab on plasma and CSF tau biomarkers in a phase 2 trial in mild to moderate Alzheimer’s disease (Lauriet)

  • Poster presentation
  • P116
  • Thu 01 December, 8:00 a.m. – 6:00 p.m.
  • Stephen Schauer, Genentech/Roche

PI-2620 Tau PET

Early [18F]-Tau PI-2620 PET signal in pre-dementia AD stages

  • Poster presentation
  • P088
  • Thu 01 Dec, 8:00 a.m. to 6:00 p.m.
  • Christina Young, Stanford ADRC

About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomere®, fuel its broad and diverse pipeline of first-class and first-class assets, which currently includes ten therapeutic candidates and three diagnostic candidates, six of which are currently in Phase 2 clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, including Roche Group member Genentech, Eli Lilly and Company and Janssen Pharmaceuticals, Inc., which has resulted in securing unrestricted funding. substantial dilution to advance its proprietary programs. and > $3 billion in potential milestone payments.

SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU and SG. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.

Information on our website and on any other websites referenced herein is expressly not incorporated by reference into, and does not form part of, this press release.

For more information, please contact:

Head of Investor Relations & Corporate Communication
Gary Waanders, Ph.D., MBA
AC Immune
Telephone: +41 21 345 91 91
Email: [email protected]


Comments are closed.